



New Member Offerings

April 21, 2026
2:00 PM (ET)

The Webinar Will Begin Shortly

- **Questions?** Please **type your questions into the Q&A box** in your Zoom control panel for our speakers.
- **Post-webinar?** A recording of this webinar will be available for future viewing of the presentation.
- **Feedback?** A survey will be available at the conclusion of the webinar. We welcome your comments!

Speakers



**Elizabeth
Gaskins Civils**
*Vice President,
Membership*



Chad Wessel
*Senior Director,
Emerging Companies
Special Initiatives*



Becky Beattie
CEO, LaunchBio



Snehal Naik
*Vice President,
Science & Regulatory
Affairs*



Tracxn Demo

Chad Wessel

Senior Director, Emerging Companies Special
Initiatives



Investor Connect PLUS

Becky Beattie

CEO, LaunchBio



LAUNCHBIO


ABOUT LAUNCHBIO

- National nonprofit supporting early-stage life science companies
- Connect founders with capital, expertise, and strategic partners
- 20,000+ members across major U.S. biotech hubs
- Programs span investor access, education, and ecosystem building
- Deep relationships with founders, investors, and industry leaders



LAUNCHBIO

INVESTOR CONNECT TO DATE



INVESTOR CONNECT

Bridging The Gap Between Innovation and Capital

- Flagship monthly, virtual investor matching program
- Curated 1:1 meetings between founders and aligned investors
- Supports Pre-Seed through Series A companies
- 51% of companies generate follow-on investor interest
- Hundreds of companies supported across therapeutic areas



LAUNCHBIO

ACCESS TO ACTIVE INVESTORS

- Venture capital, corporate venture, family offices, strategics
- Investors actively deploying capital in life sciences
- Broad sector coverage: therapeutics, medtech, diagnostics, AI
- National + global investor reach





LAUNCHBIO

INVESTOR CONNECT PLUS



- Built in partnership with BIO
- Designed for more mature, series A+ investor-ready BIO-member companies
- Focus on institutional and strategic capital
- Curated 1:1 meetings (20–30 minutes)
- Targeted, high-quality investor conversations



LAUNCHBIO

VALUE FOR BIO MEMBERS



- Direct access to aligned institutional and strategic investors
- Highly curated, targeted 1:1 meetings
- Exposure to investors actively deploying capital
- Expanded investor network beyond existing relationships
- Efficient, founder-friendly process (no wasted meetings)



LAUNCHBIO

**APPLY
TODAY**



- Applications open now for *Investor Connect Plus*
- Rolling review for qualified BIO member companies
- First investor meetings begin May 2026 and monthly thereafter



LAUNCHBIO

**STAY
CONNECTED**

- ➔ **Apply to Investor Connect Plus!**
- ➔ **Meet me at BIO at LaunchBio's Innovators Social Hour**
- ➔ **Check out more LaunchBio programs**

www.launchbio.org



The BIO Regulatory Issue Data Gathering & Engagement (BRIDGE)

Snehal Naik

VP, Science & Regulatory Affairs


BIO Regulatory Issue Data Gathering & Engagement (BRIDGE): The "WHY"



- **FDA engagement** has grown **more complex** as scientific innovation, novel modalities, and regulatory expectations continue to evolve
- **Agency resource constraints**, ambiguous guidance and **variable interpretation**, can lead to **delays and inconsistent feedback**
- **Sponsors** may receive **mixed or shifting signals** across review cycles, further increasing uncertainty
- Difficult to discern regulatory anomalies from regulatory trends. Publicly available resources often not timely
- BIO is launching the **BRIDGE** Program to collect member experiences, generate evidence-based insights, and **enable more constructive engagement and advocacy with FDA**



BIO Regulatory Issue Data Gathering & Engagement (BRIDGE): The "How"



Data

- **Member companies share FDA regulatory roadblocks/friction** via secure intake (web or phone)
- **Experienced regulatory professional** available to capture input via phone, and clarify submitted responses
- **Issue metadata captured across sponsor profile**, FDA interaction context, issue type, and impact



Insights

- Individual issues aggregated into a **centralized issue registry**
- Periodic **analysis to identify** recurring **themes**, modality- or stage-specific patterns, and process vs. interpretation signals
- **Trend-level insights distinguish from isolated cases** from systemic regulatory friction points










Action

- **Aggregated insights** used to **inform** constructive, data-driven dialogue with **FDA**
- **Focus on clarifying processes, evolving expectations, and common interpretation challenges**
- **Feedback loop** supports **upstream mitigation of friction**, improving efficiency for both sponsors and reviewers

BIO Regulatory Issue Data Gathering & Engagement (BRIDGE): : The “What”



BRIDGE will focus on capturing roadblocks or points of friction, including:

-  Change(s) in FDA regulatory requirement compared to prior FDA feedback
-  Unexpected receipt of a CRL
-  Receipt of late Information Request or feedback during the review cycle with negative impact on outcome
-  Significant delay in FDA review, meeting or decision
-  Lack of acceptance of data generated from regulatory science tools previously aligned with FDA
-  Lack of access to FDA databases/unavailability of documents online
-  Delay in inspection scheduling or delay in communicating findings (US or foreign)

BIO Regulatory Issue Data Gathering & Engagement (BRIDGE): : The “Output”



Providing tangible, high-value member benefit

- A systematic, evidence-based understanding of regulatory friction points with FDA during drug development
- A trusted foundation for constructive, timely, data-informed engagement with FDA
- Constructive visibility into areas of ambiguity enabling mutual problem solving
- Mitigation of future sponsor/FDA friction and reviewer burden, by identifying ways to resolve common procedural and interpretive issues upstream, helping sponsors engage FDA more efficiently and appropriately
- More efficient resolution of regulatory issue/roadblock points
- Learnings for future drug development regulatory strategies

Questions – Please use the Q&A function



Email for access
to Tracxn



Access the
BRIDGE Program



Apply today for
Investor Connect
PLUS



Become a BIO
Member Today